

Roberto Henrique Nussenzveig

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8431742/publications.pdf>

Version: 2024-02-01

21
papers

589
citations

933447

10
h-index

752698

20
g-index

21
all docs

21
docs citations

21
times ranked

941
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. <i>Oncologist</i> , 2021, 26, e270-e278.	3.7	33
2	Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma. <i>Journal of Urology</i> , 2021, 205, 709-717.	0.4	7
3	Identification of Somatic Gene Signatures in Circulating <scp>Cell-Free DNA</scp> Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform. <i>Oncologist</i> , 2021, 26, 751-760.	3.7	9
4	Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States. <i>Cancers</i> , 2021, 13, 4951.	3.7	19
5	Radium-223 Plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. <i>Oncologist</i> , 2021, 26, 1006-e2129.	3.7	13
6	Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer. <i>Drugs</i> , 2021, 81, 191-206.	10.9	11
7	Germline variants and response to systemic therapy in advanced prostate cancer. <i>Pharmacogenomics</i> , 2020, 21, 75-81.	1.3	2
8	Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2020, 24, 100193.	1.7	2
9	Quest for Ideal Composite Biomarkers for Response to Immunotherapies. <i>Clinical Cancer Research</i> , 2020, 26, 5059-5061.	7.0	1
10	Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. , 2020, 8, e001065.		70
11	Advanced Prostate Cancer: Treatment Advances and Future Directions. <i>Trends in Cancer</i> , 2020, 6, 702-715.	7.4	122
12	Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. <i>European Urology</i> , 2020, 78, 652-656.	1.9	64
13	Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2104-2110.	7.0	15
14	Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time. <i>Cancer Treatment and Research Communications</i> , 2019, 19, 100120.	1.7	10
15	Germline Variant in <i>SLCO2B1</i> and Response to Abiraterone Acetate Plus Prednisone (AA) in New-onset Metastatic Castration-resistant Prostate Cancer (mCRPC). <i>Molecular Cancer Therapeutics</i> , 2019, 18, 726-729.	4.1	9
16	Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2019, 125, 1459-1469.	4.1	38
17	Revisiting AJCC TNM staging for renal cell carcinoma: quest for improvement. <i>Annals of Translational Medicine</i> , 2019, 7, S18-S18.	1.7	44
18	Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. <i>Cancer</i> , 2018, 124, 2115-2124.	4.1	79

#	ARTICLE	IF	CITATIONS
19	Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 288-292.	1.9	23
20	Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e169-e172.	1.9	7
21	Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial. <i>Oncologist</i> , 2018, 23, 1413-e151.	3.7	11